Biopharmaceutical Company Announces Massive $12.5 Million Private Placement

KALA BIO, Inc. (NASDAQ: KALA), a biopharmaceutical company at the clinical stage, has recently disclosed a development involving a new securities purchase agreement. This agreement has been made with a select group of institutional accredited investors and involves the private placement of shares of its common stock and Series H Convertible Non-Redeemable Preferred Stock. The transaction promises to bring approximately $12.5 million in aggregate gross proceeds, prior to the deduction of offering expenses. $KALA BIO (KALA.US)$